Publications by authors named "R Raftopoulos"
Background: A randomized trial of phenytoin in acute optic neuritis (ON) demonstrated a 30% reduction in retinal nerve fiber layer (RNFL) loss with phenytoin versus placebo. Here we present the corresponding serum neurofilament analyses.
Methods: Eighty-six acute ON cases were randomized to receive phenytoin (4-6 mg/kg/day) or placebo for 3 months, and followed up for 6 months.
Article Synopsis
- * In a study of 43 patients, most were confirmed or probable COVID-19 cases, revealing five main categories of neurological disorders: encephalopathies, inflammatory central nervous system syndromes, ischemic strokes, peripheral neurological disorders, and other central disorders.
- * Treatment outcomes varied, with many patients showing full or partial recovery, particularly those with encephalopathy and inflammatory CNS syndromes, while some experienced severe conditions like stroke or Guillain-Barré syndrome.
Background: Acute demyelinating optic neuritis, a common feature of multiple sclerosis, can damage vision through neurodegeneration in the optic nerve and in its fibres in the retina. Inhibition of voltage-gated sodium channels is neuroprotective in preclinical models. In this study we aimed to establish whether sodium-channel inhibition with phenytoin is neuroprotective in patient with acute optic neuritis.
View Article and Find Full Text PDFOptic neuritis is a common manifestation of MS and the acute inflammatory lesion in the optic nerve resembles demyelinating plaques elsewhere in the CNS. As with other MS relapses, treatment with corticosteroids has little or no impact on the extent to which vision eventually recovers after an attack of optic neuritis. Neuroaxonal loss is now recognised as a major cause of permanent disability.
View Article and Find Full Text PDF